JP2018528258A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528258A5
JP2018528258A5 JP2018521475A JP2018521475A JP2018528258A5 JP 2018528258 A5 JP2018528258 A5 JP 2018528258A5 JP 2018521475 A JP2018521475 A JP 2018521475A JP 2018521475 A JP2018521475 A JP 2018521475A JP 2018528258 A5 JP2018528258 A5 JP 2018528258A5
Authority
JP
Japan
Prior art keywords
disease
syndrome
pharmaceutical composition
organ
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018521475A
Other languages
English (en)
Japanese (ja)
Other versions
JP6826113B2 (ja
JP2018528258A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/042074 external-priority patent/WO2017011544A1/en
Publication of JP2018528258A publication Critical patent/JP2018528258A/ja
Publication of JP2018528258A5 publication Critical patent/JP2018528258A5/ja
Application granted granted Critical
Publication of JP6826113B2 publication Critical patent/JP6826113B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018521475A 2015-07-14 2016-07-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 Active JP6826113B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562192269P 2015-07-14 2015-07-14
US62/192,269 2015-07-14
US201562197966P 2015-07-28 2015-07-28
US62/197,966 2015-07-28
US201662277201P 2016-01-11 2016-01-11
US62/277,201 2016-01-11
PCT/US2016/042074 WO2017011544A1 (en) 2015-07-14 2016-07-13 Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021003152A Division JP2021063129A (ja) 2015-07-14 2021-01-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用

Publications (3)

Publication Number Publication Date
JP2018528258A JP2018528258A (ja) 2018-09-27
JP2018528258A5 true JP2018528258A5 (enExample) 2019-08-15
JP6826113B2 JP6826113B2 (ja) 2021-02-03

Family

ID=57757587

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018521475A Active JP6826113B2 (ja) 2015-07-14 2016-07-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2021003152A Pending JP2021063129A (ja) 2015-07-14 2021-01-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2023110414A Active JP7605914B2 (ja) 2015-07-14 2023-07-05 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2024217195A Pending JP2025038055A (ja) 2015-07-14 2024-12-12 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021003152A Pending JP2021063129A (ja) 2015-07-14 2021-01-13 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2023110414A Active JP7605914B2 (ja) 2015-07-14 2023-07-05 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用
JP2024217195A Pending JP2025038055A (ja) 2015-07-14 2024-12-12 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用

Country Status (27)

Country Link
US (3) US10874738B2 (enExample)
EP (2) EP3331548B8 (enExample)
JP (4) JP6826113B2 (enExample)
KR (2) KR20250099272A (enExample)
CN (2) CN114671952A (enExample)
AU (3) AU2016294417B2 (enExample)
CL (1) CL2018000103A1 (enExample)
CO (1) CO2018001363A2 (enExample)
CR (1) CR20180097A (enExample)
DK (1) DK3331548T3 (enExample)
DO (1) DOP2018000018A (enExample)
EA (1) EA201890297A1 (enExample)
EC (1) ECSP18009949A (enExample)
ES (1) ES3075638T3 (enExample)
FI (1) FI3331548T3 (enExample)
GT (1) GT201800018A (enExample)
IL (3) IL310460A (enExample)
LT (1) LT3331548T (enExample)
MX (2) MX2018000548A (enExample)
MY (2) MY203911A (enExample)
PE (1) PE20180741A1 (enExample)
PH (1) PH12018500098A1 (enExample)
PT (1) PT3331548T (enExample)
RS (1) RS68307B1 (enExample)
SG (1) SG10201913431QA (enExample)
TN (1) TN2018000021A1 (enExample)
WO (1) WO2017011544A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913431QA (en) * 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2020056162A1 (en) * 2018-09-12 2020-03-19 Oregon Health & Science University Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival
WO2020068723A1 (en) * 2018-09-24 2020-04-02 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd154 antibody
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
CA3136725A1 (en) * 2019-04-12 2020-10-15 Tonix Pharmaceuticals Holding Corp. Inhibitors of cd40-cd154 binding
AU2020358854B2 (en) * 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CN113488170B (zh) * 2021-07-02 2023-07-25 温州医科大学 急性前葡萄膜炎复发风险预测模型构建方法及相关设备
WO2023008982A1 (ko) * 2021-07-30 2023-02-02 서울대학교산학협력단 항 cd154 항체 및 이의 용도
EP4382537A4 (en) * 2021-07-30 2025-07-23 Seoul Nat Univ R&Db Foundation ANTI-CD154 ANTIBODY AND ITS USE
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
EP4703385A1 (en) * 2023-04-28 2026-03-04 Fortvita Biologics Inc. Anti-cd40l antibody and use thereof in treatment of human autoimmune diseases
US20240392022A1 (en) 2023-05-22 2024-11-28 Genzyme Corporation Treatment of multiple sclerosis with anti-cd40l antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127351C (zh) 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6444018B1 (en) 1998-06-25 2002-09-03 Xerox Corporation Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
BRPI0809042B1 (pt) * 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
US9321833B2 (en) * 2011-04-04 2016-04-26 The Trustees Of Dartmouth College Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
WO2012138768A2 (en) * 2011-04-04 2012-10-11 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
SG10201913431QA (en) * 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Similar Documents

Publication Publication Date Title
TWI889694B (zh) 介白素-2藥劑及其用途
US7169389B2 (en) Human CD154 binding molecules and treatment methods
JP7267921B2 (ja) プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
ES2630328T3 (es) Anticuerpos anti-OX40 y procedimientos de uso de los mismos
US20080227704A1 (en) CXCL13 binding proteins
TWI496790B (zh) 介白素-１３結合蛋白質
CN108367075B (zh) 4-1bb结合蛋白及其用途
AU2013206788B2 (en) Method of providing monoclonal auto-antibodies with desired specificity
JP2022528927A5 (enExample)
JP2022513434A5 (enExample)
AU2001248350A1 (en) Antibodies to human CD154
JP2014516945A5 (enExample)
TW201031421A (en) IL-1 binding proteins
JP2020073499A (ja) インターフェロンアルファ及びオメガ抗体アンタゴニスト
JP2011520898A5 (enExample)
JP2016527187A5 (enExample)
JP2013500721A5 (enExample)
JP2015504419A (ja) Ｔ細胞反応の選択的阻害のための抗体および方法
JP2021063129A5 (enExample)
BR112013012396A2 (pt) anticorpos anti-ccl20 de neutralização
RU2010153580A (ru) Иммуноглобулины с двумя вариабельными доменами и их применение
RU2010153578A (ru) Иммуноглобулины с двойными вариабельными доменами и их применение
HK1207870A1 (en) Anti-human sema4a antibodies useful to treat disease
TW202031685A (zh) Ｌ ｉ ｌ ｒ ｂ ３ 結合分子及其用途
AU2021221123A1 (en) Anti-BCMA therapy in autoimmune disorders